Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer

JHOP - October 2022 Vol 12, No 5 - FDA Oncology Update
NEW INDICATIONS

On August 11, 2022, the FDA accelerated the approval of fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo), an HER2-directed antibody and topoisomerase inhibitor conjugate, for the treatment of unresectable or metastatic non–small-cell lung cancer (NSCLC) in adults with HER2 mutations, as detected by an FDA-approved test, who have received systemic therapy. Fam-trastuzumab deruxtecan received a breakthrough therapy designation for this indication.

The FDA concomitantly approved the Oncomine Dx Target Test for tissue and the Guardant360 CDx plasma test as companion diagnostics for fam-trastuzumab deruxtecan: the tumor tissue test should be used if no mutation is detected with the plasma test.

Fam-trastuzumab deruxtecan was previously approved for several solid tumors involving the HER2 biomarker.

“After 2 decades of research into the role of targeting HER2 in lung cancer, the approval of the first HER2-directed treatment option validates HER2 as an actionable target in lung cancer,” said Bob T. Li, MD, PhD, MPH, Memorial Sloan Kettering Cancer Center.

This approval was based on the results of the multicenter, multicohort, randomized, blinded, dose-optimization DESTINY-Lung02 clinical trial of 52 patients with unresectable or metastatic HER2-positive nonsquamous NSCLC whose disease progressed after systemic therapy.

Patients received 5.4 mg of fam-trastuzumab deruxtecan intravenously every 3 weeks until unacceptable adverse events or disease progression. The objective response rate was 58% (95% confidence interval [CI], 43%-71%), and the duration of response was 8.7 months (95% CI, 7.1-not estimable).

The most common (≥20%) adverse events were nausea, decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, decreased lymphocyte count, decreased platelet count, decreased albumin, increased aspartate aminotransferase, increased alanine aminotransferase, fatigue, constipation, decreased appetite, vomiting, increased alkaline phosphatase, and alopecia.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: